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The dicarboxyl group functions to anchor the proteins uia ca2+ ions to a
phospholipid surface in the process of coagulation. If the vitamin K-dependent
mechanism is blocked, the precursors in certain species, including man, reach the
circulation in the form of the so-called proteins induced by vitamin K absence
or antagonists (PIVKAs)
(1 )
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INTRODUCTION
This chapter is mainly devoted to the description of the specific defects of the
coagulation factors II, vII, IX and X that are caused by drugs with an
anti-vitamin K action.
vitamin K is necessary to bring about the final step in the biosynthesis of the
coagulation factors II, vII, IX and X. The normal mechanism of protein
synthesis in the liver produces individual precursor proteins for each of these
factors. A vitamin K-dependent mechanism converts glutamic acid groups in
these proteins to y-carboxy glutamic acid residues. The proteins thus modified are
the normal coagulation factors (l).
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The following subjects will be discussed in more detail:
(l) The biosynthesis of the coagulation factors II, VII, IX and X
(2) Pharmacological aspects of vitamin K antagonists
(3) The role of PIVKAs in blood coagulation
(4) Hormones and the level of clotting factors.
THE BIOSYNTHESIS OF THE COAGULATION FACTORS
il, VII, IX AND X
After it has been shown that vitamin K is not a cofactor of prothrombin,l'2 the
vitamin was thought to play a role in oxidative phosphorylation or to be a
derepressor of RNA synthesis.Ls These theories have been shown to be
untenable.G8 In addition, a role for vitamin K in peptide glycosylation and
cellular secretion has been excluded.e A hypothesis to explain the role of vitamin
K in the synthesis of factors II, VII, IX and X, now generally accepted, was
proposed on the basis of the observation that both the administration of vitamin
k-antagonists and also vitamin K deficiency resulted in the appearance of a
prothrombinJike protein in the plasma.lo From this it was inferred that vitamin
k hu, .ro influence on polypeptide synthesis p er se,blt rather modifies a protein
precursor so that it can function as a clotting factor. In the rat this mechanism has
now been largely substantiated.e Cycloheximide, a drug that blocks protein
synthesis, does not prevent a rise of prothrombin level after administration of
uitu*in K to a deficient rat, but this prothrombin does not contain labelled amino
acids administered together with the vitaminl 1 indicating th at de nouo synthesis is
adequately blocked.
It is possible to induce thrombin activity from the precursor by the use of a
proteolytic enzyme from Echis carinatus venom. By this means it can be
demonstrated that, in an animal in which protein synthesis is blocked' and which
is deficient in vitamin K, a microsomal p.ool of precursor exists. Upon
administration of vitamin K this is converted into a microsomal prothrombin
pool within minutes. This material in the course of about an hour is transferred to
ihe plasma.t2,13 The microsomal precursor and the plasmatic PIVKA may or
may- not be identical;1+16 experimental evidence on this point is inconclusive.
Precursor pools are high in species with a low plasma PIVKA level and uice
uersa.e
The vitamin K-dependent enzyme system remains largely undefined. Pre-
liminary results show that it is ATP dependente and incorporation of labelled
CO, into prothrombin has been reported.lT The nature of the vitamin K
molicule suggests that it participates in an oxido-reduction reaction. Bell and
Matschiner showed that vitamin K and vitamin K epoxide are equally active in
the rat and the chicken, but in the warfarin-treated rat, labelled vitamin K
accumulates in the epoxide form.18 It may well be that vitamin K-antagonists do
not compete with vitamin K or a vitamin K derivative at the site where this
substanci functions in clotting factor synthesis, but inhibit a conversion of the
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vitamin essential for its function. This would explain the observation that the
pharmacokinetics of the vitamin and its antagonists are more complicated than
could be explained by simple competition.le'2' Further studies by Bell and
Matschiner2l-23 showed that the epoxidewas notconverted into vitamin K in the
warfarin-treated rat and that the epoxide inhibits the action of vitamin K
competitively if measured under conditions in which it cannot become converted
into vitamin K. These workers postulate that the cycle vitamin K = vitamin K
epoxide catalysed by microsomal enzymes and inhibited by vitamin K analogues
is an essential part of the physiological mechanism completing the formation of
the coagulation factors.2l-23 observations on congenitally warfarin-resistant
rats appear to support this theory as in these animals the vitamin K oxidoreduc-
tase is insensitive to warfarin. Recent work by Sadovsky and suttie2a and
Goodman et a1.,25 however, seem to exclude this possibility. Lowenthal
suggested that coumarins act by blocking a specific cellular transport route for
vitamin K.Ie,20,26-2e
The difference between a PIVKA and a coagulation factor in its final form has
been well documented in the case of PIVKA-II and prothrombin.3o 34 From this
difference the effect of the vitamin K-dependent step on the precursor molecule
can be inferred: in prothrombin up to ten glutamyl residues are converted into 7-
cooH glutamyl residues. Such a chemical conversion-may well be associated
with an oxidation-reduction cycle. Yet the observation that co, or HCo. is
necessary for this conversion3s'36 leaves open the possibility that no oxido-
reduction is involved.
PIVKAs immunologically identical to factors IX and X have been de-
monstrated in the cow37 and in man,38 and a PIVKA-vII probably occurs in
man.3e It is likely that the vitamin K-dependent steps in the synthesis of the four
vitamin K-dependent proteins are identical (i.e. the formation of y-cooH
glutamyl residues) although the proteins differ in primary structure.aca2
PHARMACOLOGICAL ASPECTS OF VITAMIN K ANTAGONISTS
The long term administration of a coumarin congener resulting in maintenance
ofa steady blood (c.q. hepatocellular) level causes an equal degree ofinhibition of
the synthesis of the four vitamin K-dependent factors.a3 This can be deduced
from the fact that in man a steady state administration of vitamin K-antagonists
causes an equally low level of the four factors affected.aa As the plasma level
reflects a steady state in which production and breakdown counterbalance, this
means that the synthesis rate of each factor is equally reduced.
coumarin in a dose that completely blocks synthesis causes the factors to
disappear from the blood at different rates. This is because the factors have a
different biological halfJife time. Factor II disappears slowest (tLtz - 60h)
followed by factor X (tt tz - 40 h), factor IX (trrz - 20 h) and factor VII (t1l2
- 7 h). Dose variations, or variations in responsiveness resulting from the
administration of other drugs, or from gastrointestinal disturbances, fever, e/c.
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willbemostquicklyreflectedintheleveloffactorVll.Thismakesitmandatory
that an overall ,"* of,t.-Q"ick type, when used to control anticoagulant
iir.r*t, it sensitive to factor VII' Some commercial thromboplastins 
do not meet
this criterion--^b.p."ai"g 
upon the amount of coumarin congener present, 5-^25-mg vrtamrn
K,willstimulatethesynthesisofclottingfactors.Theeffectstarts2-3hafteroral
admin is t ra t ionor | |2haf te r in t ravenous in jec t ion .Grosso.modothere .
appearance of the factors occurs at the normal rate of synthesis as 
calculated
from the normal halfliie times.4s'46 Deviations from this rule can be 
explained
;;;;;;;bined action of the two complicating circumstances: firstly, 
an excess
of precursor present m the hepatocytes can bi converted quickly into 
normal
coagulation factors; and secondlY, lhel synthesis is switched 
on' the factors
synthesized are distributed between both the intravascular and extravascular
fluid.a7 A consequence of the accumulation of precursor has-been observed 
by
;;;rs";;;fi;:;;-.';"iow leu"l of anticoasulation in thg h}m1n a sufficient
doseofvitaminKinducesatemporarynserntheprothrombinleveltoabovethe
100/" level.
Bothsynthesisrateandbreakdownrateofcoagulationfactorsarostrongly
influenced by the Uu.uit*tutolic rate.ae When metabolism is increased 
(fever'
hyperthyroidism) both can be increased by a factor of two or more while in
hypothyroidism both can be decreased several-fold'as It is interesting to 
note that
synthesis and breakdown counterbalance ach other' so that change 
in metabolic
,iate do", not influence the level of coagulation factors.
THE ROLE OF PIVKAs IN BLOOD COAGULATION
The fact that coumarin congeners (and vitamin K deficiency) cause PIVKAS to
appear influences 
"ougoiuti; 
ty 
"ut'ut 
mechanisms' PIVKAs were discovered
by the fact that one of them' presumably PMA-X in the human' 
causes
inhibition of tests .rtrr" di"k ii-. typ". ttris is a complication to be 
considered
in the control or antl"oiluiunttft"tupv and can be used to diagnose 
vitamin K
deficiency. On the other i'and it has been demonstrated that PIVKA-II 
can yield
normalthrombin,albeitataslowrate,inthepresenceofnormalprothrombinase
(i.e. factor X", factor V, Ca2+ and phospholipid)' Non-physiological pro-
thrombin activators, such as staphylocoagulase or Echis carinalus 
venom'
convert pIVKA-tt lnto ttrrombin ai approximately the same rate as they 
activate
normal prothrombin. fh" l"uel of iactor II found under anticoagulation 
is
therefore dependent 
"p"" 
tit -tthod of assay used' Immunological methods'
staphylocoagulase, trfpsin and Echis carinatus y"":.-, Tt"::I !"th 
normal
prothrombin and pIViiA-II. preliminary studies in this laboratory indicate 
that
equimolar 
"on".n,rurions 
of prothrombin-and PIVKA-II will not' however'
"u',""qoul.ffectsinthesethreetests.Alsotheextenttowhichthetestsreacttoagin"n"o, '"" , , t rat ionofPIVKA-II isdependentonthetestused'Theone.stage
estimationusingeithercongenitallyfactorll-deficientplasmaoranartificial
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reagent measures only normal prothrombin. The two-stage determination, due to
the fact that normal prothrombinase slowly converts PIVKA-II into thrombin,
coestimates PIVKA-II to a degree dependent upon the technique of the
determination and the evaluation of the result.so
The inhibition of thromboplastin times bypIVKA-X means that the plasma of
an anticoagulated patient cannot be directly compared to a dilution of normal
plasma. Yet dilutions of normal plasma are the only available substance to
construct a reference curve in this type of test. Moreover, the degree of inhibition
observed at a fixed inhibitor:factor ratio is dependent upon the dilution ofthe
sample in the test system and upon the type of thromboplastin used. This has far
reaching consequences for the standardization of the iontrol of anticoagulant
treatment. For a detailed discussion the reader is referred to the pertinent
literature. s 1-s 3
HORMONES AND THE LEVELS OF CLOTTING FACTORS
The administration of sex hormones is no longer used in the treatment of young
haemophiliacs as no useful effect is obtained. yet in some cases there appears to
be an interrelationship between the level of factor IX and the hormonal stitus, for
example'inhaemophilisBr",0"..,thelevelofthjsfactorislowinchildhood( <5%),but rises to 15\ or more in puberty.sz,s+ 16" mechanism underlying this
change is still uncertain. oral contraceptives reportedly cause a rise offactors X
and vII or v, and vIII.5s-58 The interpretation of these findings should be
approached with care. on the one hand some authors do not find these rises (e.g.
Lorrain and Harel5e), on the other, a mechanism has been described that may
well explain spuriously high values of several clotting factors. Gjonnaess and
stormorken60'61 have reported that in some plasmar upon storage at 4 oc factor
vII is transformed into a more active form, probably uia the kallikrein system.
Not all plasmas show this activation; it is significantly more frequent in women
than in men, and by far the most frequent in women taking oral contraceptives.
we confirmed these findings and also found that the extent of activation depends
upon the type of thromboplastin used. It is much more evident with the use of
bovine thromboplastin than it is with human thromboplastin.62 rtis therefore
probable that the rise in clotting factor level observed by some authors is due to
activation offactor vII rather than to a higher quantity ofthis or any other factor
in the blood. It is also possible that the lowering of antithrombin itt and otherphysiological proteinase inhibitors under the influence of sex hormones observed
by some authors63'6a reflects increased consumption of these proteins due to thepresence of a high level of active proteinases.
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